{rfName}

Indexed in

License and use

Citations

Altmetrics

Analysis of institutional authors

Puig, SAuthorAlbero-Gonzalez, RAuthorIglesias, PAuthorPerez-Anker, JAuthorToll, AAuthor
Share
Publications
>
Letters

Metastatic basal cell carcinoma with neuroendocrine differentiation: complete response to cemiplimab

Publicated to:Clinical And Experimental Dermatology. 49 (9): 1060-1062 - 2024-05-27 49(9), DOI: 10.1093/ced/llae099

Authors: Marti-Marti, Ignasi; Puig, Susana; Albero-Gonzalez, Raquel; Masferrer, Emili; Iglesias, Pablo; Perez-Anker, Javiera; Serra-Garcia, Laura; Tarroch, Xavier; Curco, Neus; Toll, Agusti

Affiliations

Hosp Univ Mutua Terrassa, Dept Pathol - Author
Hosp Universitari Mutua Terrassa, Dept Neurol - Author
Inst Salud Carlos III, Ctr Invest Red Enfermedades Raras CIBERER - Author
Univ Barcelona, Hosp Clin, Dermatol Dept - Author
Univ Barcelona, Hosp Clin, Pathol Dept - Author
See more

Abstract

We report a patient with a metastatic basal cell carcinoma with neuroendocrine differentiation who responded well to cemiplimab but not to previous therapies. The different histological variants could determine treatment response.

Keywords
AgedAntibodies, monoclonal, humanizedAntineoplastic agents, immunologicalAxillary lymph nodeAxillary lymphadenopathyBasal cell carcinomaCancer chemotherapyCancer diagnosisCancer radiotherapyCancer recurrenceCarboplatinCarcinoembryonic antigenCarcinoma, basal cellCarcinoma, neuroendocrineCase reportCd56 antigenCd99 antigenCell proliferationCemiplimabChromograninClinical articleComputer assisted tomographyCytokeratin 20Cytokeratin 7Drug therapyEpidermisEpithelial cell adhesion moleculeEpithelial membrane antigenEpithelium cellErythemaEtoposideFemaleFirst-line treatmentHistopathologyHumanHuman tissueHumansImmunohistochemistryImmunological antineoplastic agentLetterLung noduleLymphadenopathyMaleMonoclonal antibodyNeuroendocrine carcinomaPathologyProstate specific antigenSkin neoplasmsSkin tumorStem cell factor receptorSynaptophysinThorax radiographyTranscription factor cdx2Treatment responseTumor biopsyTumor differentiationTumor mutational burdenUnspecified side effectVismodegib

Quality index

Bibliometric impact. Analysis of the contribution and dissemination channel

The work has been published in the journal Clinical And Experimental Dermatology due to its progression and the good impact it has achieved in recent years, according to the agency WoS (JCR), it has become a reference in its field. In the year of publication of the work, 2024 there are still no calculated indicators, but in 2023, it was in position 18/94, thus managing to position itself as a Q1 (Primer Cuartil), in the category Dermatology.

Leadership analysis of institutional authors

There is a significant leadership presence as some of the institution’s authors appear as the first or last signer, detailed as follows: Last Author (Toll Abelló, Agustín).